As per the research report, the size of the Asia Pacific Viral Inactivation Market was valued at USD 108.22 million in 2022 and estimated to be growing at a CAGR of 13.6%, to reach USD 204.73 million by 2027 during the forecast period 2022 to 2027.
One of the primary reasons driving the APAC Viral Inactivation market is the rising prevalence of infectious diseases. Furthermore, numerous government programmers to update healthcare infrastructure in various nations are fueling market expansion.
Other reasons, such as the continuous release of new medications and therapeutic goods, intensive research and development (R&D) operations, and growing consumer awareness of the transmission of blood-borne viruses via plasma, are all helping to boost the market.
Another important consideration is the growth of viruses and contamination from the selected biotherapeutic commodity during the manufacturing process; the approach is widely used in the food and blood plasma industries, where viral particles might cause problems.
To remove or inactivate potential contaminating viruses, viral inactivation is a crucial and required step in the production process of biological products. In humans, these natural products are employed for therapy and diagnosis. In addition, as the global disease burden rises, so does the need for medications, increasing the manufacturing of biologicals, injectables, and other drugs.
High costs associated with the research, manufacture, and distribution of biosimilar goods, as well as a scarcity of experienced specialists, are projected to stifle market expansion in the forecast term.
This research report on the APAC Viral Inactivation Market has been segmented and sub-segmented into the following categories:
By End User:
Geographically, the Asia-Pacific region is the fastest-growing region worldwide, with increasing numbers of new medications and government measures influenced to drive regional market growth.
The India's viral inactivation market and China's viral inactivation market are projected to reach a decent CAGR during the forecast period. Companies focused on developing technologically advanced products in countries like India, China, and Japan due to expanding R&D investments in the life science industry and improvements in Nano filtration technology are likely to increase demand for viral clearance. In addition, rising government financing for the pharmaceutical and biotechnology industries and the development of novel pharmaceuticals are expected to be fueled over the estimated period.
The APAC Viral Inactivation Market is predicted to rise in the following years, owing to rapid growth in the pharmaceutical and biotechnology sectors, an increase in the number of new drug launches, growing government backing, and substantial R&D investments in the life sciences industry.
Increase in the frequency of chronic diseases such as diabetes, cancer, autoimmune disorders, and other conditions across the Asia Pacific has increased healthcare spending. An rise in healthcare spending is mainly required to conceive and develop new and improved therapies.
Many businesses and government agencies have made significant investments in the life sciences sector in recent years. As a result, the number of innovative and alternative medicines for treating diseases, such as stem cell therapy and cellular and gene therapy, has increased significantly. Viral inactivation is a critical technique that must follow throughout the preparation of these items to avoid contamination and fatalities after human eating.
KEY MARKET PLAYERS
Top companies leading the APAC Viral Inactivation Market profiled in the report are Clean Cells, SGS S.A, Merck KGaA, Parker Hannifin, Red Source Technologies, Sartorius AG, Charles River Laboratories International Inc., Texcell Inc., Viral Inactivated Plasma Systems SA, Danaher Corporation, and WuXi Pharma Tech Inc.,
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.1 Solvent/Detergent Method
5.1.3 UV Radiation
5.1.4 Microwave Heating
5.1.5 High-Energy Light
5.1.6 Y-o-Y Growth Analysis, By Method
5.1.7 Market Attractiveness Analysis, By Method
5.1.8 Market Share Analysis, By Method
5.2.1 Kits and Reagents
5.2.4 Viral Inactivation Systems
5.2.5 Y-o-Y Growth Analysis, By Product
5.2.6 Market Attractiveness Analysis, By Product
5.2.7 Market Share Analysis, By Product
5.3.1 Vaccines and Therapeutics
5.3.2 Stem Cell Products
5.3.3 Cell Culture
5.3.4 Gene Therapy
5.3.5 Blood & Blood Products
5.3.6 Y-o-Y Growth Analysis, By Application
5.3.7 Market Attractiveness Analysis, By Application
5.3.8 Market Share Analysis, By Application
5.4 End User
5.4.1 Pharmaceutical and Biotechnology Companies
5.4.2 Contract Research Organizations
5.4.3 Academic Research Institutes
5.4.4 Other End Users
5.4.5 Y-o-Y Growth Analysis, By End User
5.4.6 Market Attractiveness Analysis, By End User
5.4.7 Market Share Analysis, By End User
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
184.108.40.206 By Method
220.127.116.11 By Product
18.104.22.168 By Application
22.214.171.124 By End User
6.1.4 Market Attractiveness Analysis
126.96.36.199 By Method
188.8.131.52 By Product
184.108.40.206 By Application
220.127.116.11 By End User
6.1.5 Market Share Analysis
18.104.22.168 By Method
22.214.171.124 By Product
126.96.36.199 By Application
188.8.131.52 By End User
6.5 South Korea
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Clean Cells
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Charles River Laboratories International Inc.
8.3 Danaher Corporation
8.4 Merck KGaA
8.5 Parker Hannifin
8.6 Red Source Technologies
8.7 Sartorius AG
8.8 SGS S.A
8.9 Texcell Inc
8.10 Viral Inactivated Plasma Systems SA
8.11 WuXi Pharma Tech Inc.
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.